Free Trial

Senseonics Q2 2023 Earnings Report

Senseonics logo
$0.46 +0.02 (+4.03%)
(As of 12/20/2024 05:45 PM ET)

Senseonics EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.04
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Senseonics Revenue Results

Actual Revenue
$4.13 million
Expected Revenue
$4.59 million
Beat/Miss
Missed by -$460.00 thousand
YoY Revenue Growth
N/A

Senseonics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Wall Street Icon: “You must get on the right side of this thing” (Ad)

I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.

This market shakeup is going to be much more intense.

Senseonics Earnings Headlines

Senseonics provides update on Eversense 365 launch
Senseonics Holdings, Inc. Provides Update on Eversense 365 Launch
Wall Street Icon: “You must get on the right side of this thing”
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
Senseonics Holdings Expands with Innovative Diabetes Solutions
Senseonics Holdings Reports Q3 2024 Earnings Results
See More Senseonics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senseonics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senseonics and other key companies, straight to your email.

About Senseonics

Senseonics (NYSE:SENS), a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

View Senseonics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings